G1 Therapeutics
700 Park Offices Drive
Suite 200
Research Triangle Park
North Carolina
27709
United States
Website: http://www.g1therapeutics.com/
204 articles about G1 Therapeutics
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2022
1/3/2022
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of G1’s common stock to three employees under the G1 Therapeutics, Inc.
-
G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force
12/16/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the Company will hire and deploy an additional 20 salespeople, bringing the total number of oncology sales representatives to 34.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor Microenvironment
12/1/2021
G1 Therapeutics, Inc. today announced that the Company has initiated a Phase 2, single arm, open-label study of trilaciclib in patients with early-stage triple negative breast cancer (TNBC).
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 01, 2021
12/1/2021
G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for an aggregate of 101,700 shares of G1’s common stock to seven employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan, and an aggregate of 56,400 shares of G1’s common stock to eight employees under the previously-announced G1 Therapeutics, Inc. 2021 Sales Force Inducement Equity Incentive Plan.
-
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC)
11/29/2021
G1 Therapeutics, Inc. today announced that the Company has initiated a Phase 2, single arm, open-label study of trilaciclib administered prior to the antibody-drug conjugate (ADC).
-
Clinical Catch-Up: November 15-19
11/22/2021
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look. -
Immune Analysis from Phase 2 Triple Negative Breast Cancer Trial Demonstrates Trilaciclib Enhanced Patients’ T Cell Immune Function When Administered Prior to Chemotherapy
11/12/2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results from an immunologic analysis of Phase 2 study data showing that trilaciclib enhances both CD4 and CD8 T cell function in certain patients with metastatic triple negative breast cancer (mTNBC) when administered prior to chemotherapy.
-
G1 Therapeutics to Participate in Two Upcoming Conferences
11/10/2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences.
-
G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights
11/3/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the third quarter ended September 30, 2021.
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 01, 2021
11/1/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 13,000 shares of G1’s common stock to one employee under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan, and an aggregate of 48,600 shares of G1’s common stock to one employee under the previously-announced G1 Therapeutics, Inc.
-
G1 Therapeutics to Provide Third Quarter 2021 Financial Results and Business Update on November 3, 2021
10/20/2021
G1 Therapeutics, Inc. will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2021 on Wednesday, November 3, 2021 at 8:30 a.m. ET.
-
Retrospective Analysis of Pooled Results from Three Studies Shows COSELA™ (Trilaciclib) Reduced Use of Supportive Care Interventions in Extensive Stage Small Cell Lung Cancer Patients Who Receive the Drug Prior to Chemotherapy
10/7/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced results from a retrospective analysis of the pooled results of three randomized trilaciclib studies showing that patients with extensive-stage small-cell lung cancer who received the drug prior to each chemotherapy treatment had significantly lower use of supportive care therapies for chemotherapy-induced myelosuppression than patients who received placebo.
-
G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid Services
10/1/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the permanent J-code for COSELA™ that was issued in July 2021 by the Centers for Medicare & Medicaid Services is now effective for provider billing for all sites of care.
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021
10/1/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 62,100 shares of G1’s common stock to six employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
-
G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force
9/15/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced that it will hire and train a 15-person oncology sales force to supplement the Boehringer Ingelheim oncology commercial team.
-
G1 Therapeutics to Participate in Two Upcoming September 2021 Conferences
9/3/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the Company will participate in two upcoming virtual investor conferences in September.
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 03, 2021
9/3/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 43,400 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
-
G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights
8/4/2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the second quarter ended June 30, 2021.